Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...

CirCode Biomed’s circular RNA drug HM2002 has received IND clearance from the FDA for the treatment of ischaemic heart ...

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other ...

The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...

Telesis Bio has announced a licensing agreement with Regeneron, enabling the latter to deploy the Gibson SOLA platform at R&D ...

Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.